S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Will NIO Partake In China's Economic Awakening?
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Tax Software Specialist Vertex In Buy Zone After Base Breakout
NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Forecast, Price & News

$73.74
-1.50 (-1.99%)
(As of 06/9/2023 ET)
Compare
Today's Range
$73.12
$75.80
50-Day Range
$58.41
$80.22
52-Week Range
$20.63
$82.85
Volume
421,868 shs
Average Volume
861,002 shs
Market Capitalization
$3.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$105.57

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
43.2% Upside
$105.57 Price Target
Short Interest
Bearish
21.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
1.42mentions of Axsome Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.84) to ($1.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

251st out of 987 stocks

Pharmaceutical Preparations Industry

113th out of 479 stocks


AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Axsome Therapeutics (NASDAQ: AXSM)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Axsome: Promising Early Launch
3 Growth Stocks to Buy and Hold
See More Headlines

AXSM Price History

AXSM Company Calendar

Last Earnings
5/08/2023
Today
6/10/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$105.57
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+43.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Net Income
$-187,130,000.00
Net Margins
-109.75%
Pretax Margin
-107.97%

Debt

Sales & Book Value

Annual Sales
$50.04 million
Book Value
$2.52 per share

Miscellaneous

Free Float
32,898,000
Market Cap
$3.21 billion
Optionable
Optionable
Beta
1.92

Key Executives

  • Herriott Tabuteau
    Chairman & Chief Executive Officer
  • Mark L. Jacobson
    Chief Operating Officer
  • Nick PizzieNick Pizzie
    Chief Financial Officer
  • Lori Englebert
    Executive VP-Commercial & Business Development
  • Kevin Laliberte
    Executive Vice President-Product Strategy













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2023?

13 brokers have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $52.00 to $200.00. On average, they anticipate the company's stock price to reach $105.57 in the next year. This suggests a possible upside of 43.2% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the start of the year. Since then, AXSM stock has decreased by 4.4% and is now trading at $73.74.
View the best growth stocks for 2023 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, May, 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.91. The business earned $94.58 million during the quarter, compared to analysts' expectations of $26.87 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 152.04% and a negative net margin of 109.75%.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (8.68%), BlackRock Inc. (5.67%), BVF Inc. IL (4.89%), FMR LLC (3.13%), State Street Corp (1.83%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $73.74.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $3.21 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -